NLRP3 and delirium: PI3K-Akt signaling pathway has been reported in the many cancers, and a study of Qiu et al. [30] showed that 5-HT(1A) receptor antagonist could improve the symptoms of delirium rats at some extent via inhibiting NLRP3 activity induced by PI3K/Akt/mTOR activation.